Are all psilocybin mushrooms the same?

Published 16 September 2026Last reviewed 2 October 2026

A question that comes up in almost this exact form: are they all basically the same, and is the only real difference how much you take?

No. And the interesting part is where the differences actually sit, because it is not where the marketing puts them.

Species and strain are two different words pretending to be one

A species is a taxonomic unit. It has a formal name, a published description, deposited reference material, and a literature you can argue with.

A strain, in this world, has a name someone chose. There is no registry of psilocybin mushroom cultivars, no deposited type specimen, and no chain of custody that lets anyone confirm that two cultures sold under the same name are the same organism. We have not identified any such registry. So when two vendors both sell something under one familiar name, nothing in the system guarantees they hold the same thing, and nothing would preserve a real chemical difference even if one existed.

Where do those names come from? Some claim a place of origin. Some describe a shape or a colour. Some claim a cross between two other names. Some are simply marketing. None of them is chemical evidence.

One case is worth naming because it is a clean example of the confusion. "Natal Super Strength" is traded as a strain. Psilocybe natalensis is a separate species. In the controlled dataset we have identified that includes it, a reference-material study in which six Psilocybe species were grown under uniform conditions and identified by DNA, it measured in the middle of the range for psilocybin, not at the top. It was not among the fourteen strains in the comparison described in the next section, which looked at one species only. So the name gets the taxonomic level wrong, and we have not identified a controlled test of the strength claim. It is not disproven either, and that distinction matters more than people think.

What a controlled comparison actually found

In 2026 a group published a comparison of a kind we had not identified before: fourteen Psilocybe cubensis strains, all grown, dried, extracted and analysed under one uniform protocol, with six compounds quantified. Total tryptamine content varied by more than 7.8-fold across the fourteen. That is a real, measured difference, and it is large.

Now put it next to a genomic result from 2023. Sequencing 38 isolates from naturalized Australian populations against 86 commercially available cultivar genomes showed that the alleles of the psilocybin gene cluster are identical across most cultivars, with low diversity in the coding sequence. The cultivated population carries every signature of domestication, including low effective population size, hallmarks of selfing and clonal propagation, and low allelic diversity in mating genes.

These two findings look like a contradiction and are not one. One study sequenced genes. The other measured product in the fruiting body. Enzymes with identical sequences can make very different amounts of a compound, which is ordinary biology. What the pair suggests is that the chemical variation is real, while the coding sequence of that gene cluster is identical across most of the cultivars sequenced, so differences in that sequence are unlikely to be the main explanation. The sequencing authors add their own caution: the unique allelic diversity they did find in Australia and in some cultivars may translate into differences in how psilocybin and its analogs are made. The two studies also examined different sets of material, so the comparison is indirect.

There is a second limit on the strain comparison, and the authors of it flagged it themselves. The strain identities were confirmed phenotypically, against declared culture names and published descriptions, in the absence of a comprehensive genetic reference database. So the study demonstrates 7.8-fold variation between things labelled as different strains. It does not demonstrate that each label is a distinct genotype.

Two mushrooms from the same tub

Here is the number that quietly ends most strength arguments. In that same uniform-protocol study, five individual fruiting bodies of each of six strains, grown side by side in one chamber, differed in psilocybin content. Within a strain, the coefficient of variation ranged from 12.81% to 23.39%, depending on which strain was examined.

That is the noise floor. A 15% gap between two samples is not a finding. It is within the expected spread of the same biological unit.

The mushroom is not one material

Break a mushroom apart and you get different chemistry from different pieces. In a study of one cultivated culture, caps and stems were quantified separately across seven sample sets. By our arithmetic from the means the authors report, psilocybin concentrated in the caps by roughly 1.6-fold, and psilocin by roughly 3.1-fold.

The ratio between the compounds changes too, and not just the total. Two samples from the same harvest, one of caps and one of what was left over, are not the same material in the chemical sense. Even before caps and stems are separated, the whole-fruit psilocybin values across those seven sample sets of one culture ran from 10.6 to 25.7 mg per gram, about 2.4-fold.

"Whole fruiting body" turns out to be a definition rather than a fact. Its value depends on the cap-to-stem mass ratio of that particular harvest.

What happens after harvest is bigger than everything above

The mushroom keeps changing once it is picked. Psilocybin, the stable phosphate ester, converts to psilocin, which is the sensitive one, and psilocin then oxidises and degrades.

In controlled cultivation work published in the January 2026 issue of the Journal of AOAC International, storing fresh mushrooms in a freezer before freeze-drying dropped psilocybin from 1.29% to 0.08% in one species, and raised psilocin at the same time. Those are data the authors themselves call preliminary. Even so, they describe more than a fifteen-fold move, from one technical handling step that is rarely reported at all.

The reverse also holds. In work from a legally sanctioned laboratory in Jamaica, encapsulated biomass held its tryptamine content stably for eleven months. Stability is achievable. It is a function of processing and packaging, which means it is a parameter that can be standardised, and that is the whole point.

Even the summary number is ambiguous

Suppose two honest laboratories analyse the same sample and both report "total tryptamines." They can legitimately publish different numbers.

Psilocybin and psilocin have different molecular weights. Some laboratories add the masses directly. Others convert psilocin to a psilocybin-equivalent basis before adding, which multiplies the psilocin component by about 1.392. The difference between the two conventions is roughly 39% of the psilocin component. In a fresh, well-handled sample that barely matters. In a badly handled one, where psilocin has become a major component, it matters a lot.

There is a quieter problem in the same family. The plus-minus sign after a reported mean is used for standard deviation, for standard error, and sometimes for a range, and many papers do not say which. One published value reads as a standard error once you check it against the reported range, meaning the true spread is considerably wider than it looks.

Stack it up

Most of these have nothing to do with genetics at all. They arise at different steps, so most of them are independent of each other and can compound. Two rows are not independent: the two cap versus stem rows are one split seen in two compounds, so they should not be stacked on each other.

Which is why Metanoia does not rank strain potency, and will not. A potency figure reported without developmental stage, mushroom part, post-harvest handling and analytical method is not a data point. It is a rumour with a decimal place.

So this is a record-keeping problem

That table is the argument for the thing we are actually building.

If variation in the material is the same size as the effect anyone is trying to study, then studies that do not record the material are not comparable to each other. The fix is not a better guess. It is a record with mandatory fields.

Some of that work is already under way elsewhere, and it is being done well. The January 2026 issue of the Journal of AOAC International carried a dedicated section on psychedelic plants and fungi, including a single-laboratory validation of a method covering 26 compounds in botanical material, run to United States Pharmacopeia guidelines. AOAC INTERNATIONAL writes the official methods that regulators point to. A standard for reporting the material is being built by a body with the standing to make it stick, and our position is to align with it and not duplicate it.

Two small fields we think are missing from any such record, and both came out of reading one paper closely. First, how the "total" figure was calculated, since without that it cannot be compared to any other total in the world. Second, what the plus-minus actually represents, along with the number of replicates. "Not stated" is a legitimate and common value for both. Recording it is the entire point.

What we do not know

We have not identified an inter-laboratory comparison of one sample across the main analytical platforms. The whole chain of comparison in the literature rests on the assumption that those platforms substitute for each other, and that assumption has not been tested.

We have not identified a study running the same strains across several growing environments. That is the test that would separate genetic production capacity from distance to each strain's own optimum, and it is neither expensive nor complicated.

We have not identified a cultivar registry with deposited type specimens, and at least one controlled study has already found the standard barcoding marker too coarse to tell these cultivars apart: in the fourteen-strain comparison, thirteen of the fourteen were identical at that marker.

We have not identified a published quantitative curve of tryptamine loss against drying temperature and time. That one is a gap Metanoia could fill with equipment instead of expensive instrumentation, and it sits on our list.

Sources

• 1. Sharchaton A, Parsha S, Azerrad SP, Dekel Y, Rabah N, Páleníček T, Kurzbaum E. Surprising variability in tryptamine profiles of Psilocybe cubensis fruiting bodies: inter- and intra-strain differences across 14 strains cultivated under controlled conditions. J Fungi 2026;12(7):486.

  PMID 42506248 · DOI · Level 1. 7.8-fold between strain labels. Within-strain CV for psilocybin 12.81% to 23.39% across six strains, five fruiting bodies each. Strain identity confirmed phenotypically in the absence of a genetic reference database. Thirteen of fourteen strains identical at the ITS2 barcoding marker.

• 2. McTaggart AR, McLaughlin S, Slot JC, McKernan K, et al. Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations. Curr Biol 2023;33(23):5147–5159.

  PMID 38052161 · DOI · Level 1. Psilocybin cluster alleles identical across most cultivars. Domestication signatures. The authors describe the Australian isolates as naturalized, not wild.

• 3. Windsor C, Kreynes AE, Chilton JS, Chioffi WA, Niebergall C, Dodds K. Development of Psilocybe mushroom species reference material: cultivation parameters and chemical profiles. J AOAC Int 2026;109(1):37–50.

  PMID 39960890 · DOI · Level 1. Six species under controlled cultivation, DNA-confirmed. P. natalensis is one of the six and sits in the middle of the psilocybin range. Freezing before freeze-drying dropped psilocybin from 1.29% to 0.08%. Authors employed by a commercial supplier and describe the storage data as preliminary, both stated in the article text.

• 4. Miller DR, Jacobs JT, Rockefeller A, Singer H, Bollinger IM, Conway J, Slot JC, Cliffel DE. Cultivation, chemistry, and genome of Psilocybe zapotecorum. J Psychedelic Stud 2024;8(1):63–81.

  PMID 41836496 · DOI · Level 1. Cap and stem quantified separately, seven sample sets. Cap-to-stem ratios of 1.6 and 3.1 are Metanoia's calculation from the reported means, not values the authors presented.

• 5. French T, Fontana AJ, LaBudde R, Brunelle SL, Sudberg S. Determination and confirmation of psychedelic and psychoactive compounds in botanical materials by UPLC-ESI-MS/MS: single-laboratory validation. J AOAC Int 2026;109(1):61–74.

  PMID 41014027 · DOI · Level 1. 26 analytes, validated to USP <1225> and AOAC Appendix K. Authors include a commercial testing laboratory.

• 6. Foster K, Morrison I, Daniel S, Antoine J, Thankappan B, De La Haye W, Tyler M, Grant C, Delgoda R. Toward standardized products containing biomass of Psilocybe cubensis fungi. J AOAC Int 2026;109(1):51–60.

  PMID 40802522 · DOI · Level 1. Encapsulated biomass stable for 11 months. Batch variability explicitly reported by the authors.

• 7. Brunelle SL. Psychedelic plants and fungi: regulatory landscape, analytical challenges, and quality considerations. J AOAC Int 2026;109(1):34–36.

  PMID 41052267 · DOI · Level 1. Section introduction, evidence that the material standard moved into a standards body.

Bibliographic source for all identifiers above: PubMed. Identifiers 1 to 6 were re-verified directly against PubMed on 16 September 2026. The titles of sources 1 and 4 were checked against the PubMed and Crossref records and corrected to the published wording on 2 October 2026.

See the records we're building   Back to Education